Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Friday. Several other equities analysts also recently commented on AMPH. Jefferies Financial Group assumed coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, July 25th. … Read more
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) CFO William J. Peters sold 60,743 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $51.75, for a total value of $3,143,450.25. Following the completion of the sale, the chief financial officer now directly owns … Read more
Russell Investments Group Ltd. trimmed its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 50.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,216 shares of the company’s stock after selling 36,886 shares during the quarter. Russell Investments Group Ltd. owned … Read more
Cornercap Investment Counsel Inc. reduced its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 14.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,233 shares of the company’s stock after selling 5,813 shares during the period. … Read more
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday. A number of other brokerages have also recently issued reports on AMPH. Piper Sandler raised their price objective on shares of Amphastar Pharmaceuticals from … Read more
Summit Global Investments boosted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 26.4% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 37,300 shares of the company’s stock after purchasing an additional 7,800 shares during the period. Summit Global Investments owned about … Read more